Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2008-04-11
2010-11-02
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C435S007400, C530S388260
Reexamination Certificate
active
07824682
ABSTRACT:
The present disclosure provides a cDNA, protein sequence, and genomic structure of the human cardiac isoform of myosin light chain kinase (cMLCK), and describes mutations in the cMLCK gene that are associated with cardiac dysfunction. Methods are provided for identifying individuals who can harbor mutations in the cMLCK gene, or carry alleles that can predisposed them to cardiac dysfunction. Disclosed also is a significant role for cMLCK in modulating cardiac contractility. The cMLCK protein is shown herein to reduce the amplitude of stretch activation and increase the tension production, a property of muscle which has heretofore had an unknown role in cardiac contraction. Moreover, the cMLCK protein is shown to be regionally distributed in the heart, thereby having differential effects on contractility and stretch activation. Methods herein are provided to exploit this effect of cMLCK, to treat individuals who have or are prone to cardiac dysfunction. In addition, methods are provided to identify agents that modulate cMLCK activity, thereby having potential therapeutic importance in the treatment of cardiac dysfunction.
REFERENCES:
patent: 6730491 (2004-05-01), Kapeller-Libermann et al.
patent: 0 357 856 (1990-03-01), None
patent: WO 01/38503 (2001-05-01), None
patent: WO 01/64905 (2001-09-01), None
patent: WO 01/85767 (2001-11-01), None
patent: WO 01/96547 (2001-12-01), None
Attwood, Science 290: 471-473, 2000.
Skolnick et al., Trends in Biotech. 18: 34-39, 2000.
Lederman et al., Molecular Immunology 28: 1171-1181, 1991.
Li et al., PNAS 77: 3211-3214, 1980.
Bost et al., Immunological Investigation 17: 577-586, 1988.
Bendayan, J. Histochem. Cytochem. 43: 881-886, 1995.
Aoki et al.,Nature Medicine6(2):183-188 (2000).
Gallagher et al.,Journal of Muscle Research and Cell Mobility18:1-16 (1997).
GenBank Accession No. AF325649 (Mar. 9, 2001).
GenBank Accession No. AL160175 (Mar. 13, 2000).
Herring et al.,Am. J. Physiol Cell Physiol279:C1656-C1664 (20000).
Herring et al.,Journal of Biological Chemistry265(3):1724-1730 (1990).
International Search Report from PCT Application No. PCT/US01/28639, 6 pages, mailed Sep. 16, 2002.
Janko P, “On the activation mechanism of cardiac myosin light chain kinase,” 1992, Hormones and Cell Regulation, 6:27-35.
Liu et al.,J. Mol Cell Cardiol27:2613-2621 (1995).
Poetter et al.,Nature Genetics13:63-69 (1996).
Roush et al.,The Journal of Biological Chemistry263(11):10510-10516 (1988).
Seffernick et al., J. Bacteriology, 183:2405-2410, 2001.
Vemuri et al.,Proc. Natl. Acad. Sci. USA96:1048-1053 (1999).
Wells, Biochemistry, 29:8509-8517, 1990.
Davis, et al., “The Overall Pattern of Cardiac Contraction Depends on a Spatial Gradient of Myosin Regulatory Light Chain Phosphorylation,” Cell, 107:631-641 (Nov. 30, 2001).
Davis Julien S.
Epstein Neal D.
Hassanzadeh Shahin
Winitsky Steve O.
Gambel Phillip
Klarquist & Sparkman, LLP
The United States of America as represented by the Department of
LandOfFree
Cardiac myosin light chain kinase-specific antibodies and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cardiac myosin light chain kinase-specific antibodies and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cardiac myosin light chain kinase-specific antibodies and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4236556